Latest news with #Augmentation
Yahoo
3 days ago
- Business
- Yahoo
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
BEDFORD, Mass., August 07, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. An archived replay of the webcast will be available for at least 90 days following the event. About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Times
13-06-2025
- Entertainment
- Times
Only singing can save Clapham Common from the apocalypse
Imagine, if you will, a near future in which the wildfires are 'raging outside of Milton Keynes'. Unless it was protected inside the lush 'biodomes' dotted around the country, the remaining greenery has withered and died amid extreme weather and scorching temperatures. Like the rest of the 16-year-olds in this world, Akaego is awaiting the big day — Augmentation Day — when her unique talents will be 'surgically enhanced to ensure the survival of society'. She is one of the few people who have the power to accelerate the growth of plants — a precious talent in a climate apocalypse that is killing off the source of so many foods and medicines. As Augmentation Day approaches, she receives a mysterious note. 'Whatever happens,' it warns, 'don't get Augmented.' Why not? What does the rebel group of 'Freestakers' know that she doesn't? What secrets are her parents keeping? And what really happened at that 'aerogel manufacturing plant in Croydon 13 years ago'? The author Kenechi Udogu was highly commended in the Fab Prize, the Faber competition aimed at spotting new talent, and Augmented has first-novel energy. The premise is strong. Akaego can use her voice to grow plants; she just needs to fine-tune her frequency: 'The first note came out louder than I'd expected. […] The second also felt off. Like it was catching in my throat, reluctant to escape into the world. My head tilted backwards with the next note. This one had more of a melody to it, and I latched on to it. Unlike the others, it felt light, like it wanted to roam free, like it wanted to be more than just air trapped within my body.' A musical mission to save the planet? I'm here for it. I was looking forward to our heroine bringing plants to life like Spielberg's ET resurrecting that dead chrysanthemum. • Eight books to get your child excited about reading However, no sooner has Akaego's superpower been introduced, her Midas touch is all but forgotten and her story is left to wither in favour of a much less interesting one involving the internal wranglings between some rather dull rebels and the mayor's office. (Something about only certain classes of people being allowed licences to grow their own. As the story goes on, there's less about planet-saving soundwaves and more secondary characters turning up to say things like, 'It still doesn't give them the right to stop people from trying to create equally sustainable societies which can function outside of theirs.') So the concept is promising, but the writing is clunky. As she considers the desolate landscape that was once Clapham Common, Akaego imagines 'what spaces like this would be like if I could help rejuvenate them. If the ability everyone believed I had would be able to provide more enclosed green leisure spaces for people to enjoy.' • Read more book reviews and interviews — and see what's top of the Sunday Times Bestsellers List Thankfully, there's a sweet and gentle romance, and enough interesting ideas to keep things thrumming, if eco-sci-fi is your thing. Augmented (12+) by Kenechi Udogu (Faber £8.99 pp391). To order a copy go to Free UK standard P&P on online orders over £25. Special discount available for Times+ members
Associated Press
29-05-2025
- Business
- Associated Press
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--May 29, 2025-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 1:25 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company's proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit View source version on CONTACT: Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302Doug Snow Director, Communications & Investor Relations [email protected] 508-642-6485 KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA GENETICS CLINICAL TRIALS SOURCE: Stoke Therapeutics, Inc. Copyright Business Wire 2025. PUB: 05/29/2025 07:30 AM/DISC: 05/29/2025 07:31 AM
Yahoo
01-04-2025
- Business
- Yahoo
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 01, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company's proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
